

Prospects of Differentiation Therapy for Cancer Stem Cells

Shigekazu Murakami and Fumio Tashiro*

Department of Biological Science and Technology, Tokyo University of Science, Nijuku 6-3-1, Katsushika-ku, Tokyo 125-8585, Japan

Abstract

The subpopulation of cancer stem cells (CSCs) in tumor tissues drives tumorigenesis and causes the infiltration of cancer cells to surrounding tissues. CSCs are considered to induce tumor initiation, progression, and relapse. Conventional chemotherapies eliminate bulk tumors; however, CSCs evade most therapies. We recently showed that differentiation of CSCs in hepatocellular carcinoma diminished malignant phenotypes. The best strategy for CSC-targeting therapy is yet unknown, however, it appears that differentiation therapy would be effective for certain types of tumors. In this review, we discuss the characteristics of CSCs and prospective use of differentiation therapy for cancer stem cells.

Keywords: Cancer stem cells; Differentiation therapy; Chemoresistance; Hepatocellular carcinoma; SRY; OCT4; ABC transporter

Introduction

Cancer stem cells (CSCs) are one of the promising areas of cancer research. Several researchers have focused on the understanding of CSCs after the existence of CSCs in leukemia was described in 1994 [1]. The concept of CSCs explains the phenomenon that malignant status correlates to the existence of CSC-like cells [2]. It is essential to understand the biology of CSC to develop a strategy to eradicate cancer. In various cases, malignant tumor tissues include CSCs, which overcome various anticancer therapies targeting specific proteins despite the temporary effect against the progression of cancer. Given that numerous genes are involved in cellular processes in CSC cell cycles, researchers are yet struggling to find promising cancer therapies.

It has been assumed that CSCs originate from dysregulated behavior of normal tissue stem cells and is limited to a hematopoietic or germ cell lineage [3], however, several types of solid tumors appear to include these aberrant CSCs [4-6].

In fact, non-CSCs and normal cells form CSC-like cells [7]. Several gene sets have been identified to have the potential to transform cancer cells into CSCs or maintain the homeostasis of CSCs. For example, epithelial to mesenchymal transition (EMT) inducers are representative functional markers for the acquisition of a stem-like state in cancer cells [8]. ATP-binding cassette (ABC) transporter proteins in CSC-like cells function to secure genomic stability and prevent apoptosis by efflux of cytotoxic agents [9]. It is important to understand the highly complicated signaling mechanism, which sustains the CSC biology.

Inhibiting one of the important pathways for CSC causes the activation of the bypass pathway; therefore, some researchers are seeking a different approach. This approach originates from the ideas of differentiation, which causes leukocyte-initiating cells (LIC) to differentiate into terminally differentiated leukocytes [10,11]. The induction of differentiation has expanded to solid tumors [12]. In this manuscript, we discuss the induction of CSC differentiation based on our recent findings. We have demonstrated the multipotency of CSC in hepatocellular carcinomas (HCC), which implies that CSCs have a potential of multi-lineage differentiation. This strategy would provide novel CSC-targeting therapy.

Characteristics of cancer stem cells

Recent studies have demonstrated that cancer stem cells or cancer-

initiating cells with tumor-initiating ability and self-renewal capacity are involved in tumor initiation, metastasis, and relapse [13,14]. It appears that the field of breast cancer contributed considerably to uncovering the biology of CSC [15]. Subpopulations with the cell surface marker CD44⁺CD24^{low} were identified to be tumorigenic cancer cells [16]. EMT is the critical step for acquiring stem cell features [17]. Plasticity of CSCs between epithelial- and mesenchymal-like CSCs is involved in cancer progression by promoting tumor growth and metastasis [18]. In HCC, multiple CSC markers have been identified, including CD13, CD44, CD90, and CD133 [19-21]. Although it remains unclear when CSCs are generated, premalignant lesions of HCCs have CD44-positive CSC-like populations, which can initiate tumor formation by autocrine IL-6 signaling [22]; this suggests that they are required for tumor initiation of HCCs. With regard to the association between CSCs and metastasis, CSCs were found in the bloodstream of patients with HCC [21,23]. Circulating tumor cells (CTCs) are considered to be undergoing metastasis. CTCs are detected in early stages of prostate cancer in patients [24], and clusters of CTCs are more resistant to apoptosis and an increase in metastatic potential [25]. CTCs have been found in different types of cancer patients [26,27]. When combining all of these reports, it is possible that CSCs appear in relatively early stages of a tumor and contribute to both tumor initiation and metastasis.

Tolerance against chemotherapy in cancer stem cells

Eliminating CSCs from tumor tissue is the most desirable cancer therapy because these cells play important roles in cancer progression. CSCs can survive in severe conditions, although most cancer cells die under these conditions. Shutdown of an important signaling pathway for cancer cells can regress bulk tumor; however, CSCs survive by releasing various agents to the extracellular environment. It has clarified that chemoresistance in CSCs depends on efflux by the ABC transporter gene family, MDR1 (ABCB1) and BCRP (ABCG2), which

***Corresponding author:** Fumio Tashiro, Department of Biological Science and Technology, Tokyo University of Science, Nijuku 6-3-1, Katsushika-ku, Tokyo 125-8585, Japan, Tel: +813-5876-1717; E-mail: ftashir@rs.noda.tus.ac.jp

Received October 16, 2015; **Accepted** October 26, 2015; **Published** November 02, 2015

Citation: Murakami S, Tashiro F (2015) Prospects of Differentiation Therapy for Cancer Stem Cells. Adv Tech Biol Med 3: 144. doi: [10.4172/2379-1764.1000144](https://doi.org/10.4172/2379-1764.1000144)

Copyright: © 2015 Murakami S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

were originally found in hematopoietic stem cells by the side population (SP) assay [28,29]. The SP assay is the method for identifying CSCs using the efflux of the DNA-binding dye Hoechst 33342 [30,31]. The expression level of the ABC transporter gene correlates with stem cell compartment characterized by SP. *MDR1* gene knockout mice were viable and fertile, but showed an increased sensitivity to drugs [32], suggesting that the ABC transporter is important for resistance to chemotherapy. However, the transporter is not critical for stem cell growth. BCRP is described as an essential multidrug transporter against mitoxantrone, doxorubicin, and daunorubicin in breast cancer [33]. To date, the subfamily of ABC transporter genes has been identified, including the ABCA, ABCB, ABCC, and ABCG subfamilies, and play an important role in the efflux of the vast number of anticancer drugs [34]. In melanoma, anticancer drug treatment with vemurafenib and dacarbazine resulted in the selection of ABCB5-expressing cells [35]. The nuclear membrane is important for securing genomic stability. ABCC2 is localized to the nuclear membrane [36] and involved in resistance to several types of chemotherapeutic agents [37-40]. These studies imply that current chemotherapy should focus on certain types of cancer cells, particularly CSCs.


Key signaling pathway in CSCs

Embryonic stem cell (ESC) signatures including OCT4, SOX2, and NANOG, are involved in the development of various types of tumors [41-44]. They play critical roles during embryonic development and are required for pluripotency of induced pluripotent stem (iPS) cells [45]. Because ESC signatures have several downstream genes, their target genes are widespread in oncogenes [46]. Oct4 upregulates CSC markers, and OCT4 and NANOG overexpression promote EMT by increasing the expression of Snail and Slug [47,48]. OCT4 is required for chemoresistance by regulating the ABC transporter [49-51]. The expression of Sox2 is enriched in the CSC population with high expression levels of CD44 and directly binds to *Snail*, *Slug*, and *Twist* promoters, promoting EMT in pancreatic cancer cells [52]. SOX2 regulates self-renewal and tumorigenicity of CSC-like cells [53]. NANOG has a similar function for CSC and drug resistance, whereas NANOG interacts with CD44 and activates the STAT3 signaling pathway [54]. The reciprocal relationships among ESC genes, micro RNA, and polycomb complexes have also been investigated [55]. These findings provide the basis for the idea that dysregulation of ESC signatures can trigger multi-events important for cancer cells.

CSCs demonstrate that signal transduction pathways, activated in tissue development and homeostasis, have an effect on their state. Notch, Hedgehog (HH), and Wnt signaling pathways have been considered to be targets for overcoming CSC-associated primary or acquired resistance to cancer treatment [56]. In normal stem tissues, HH and Wnt feedback is associated with the proliferation of epithelial stem cells [57]. It is well known that stem cell compartments exist within stem cell niches, and these signaling pathways are important for stem cell niches in tissue homeostasis [58,59]. However, in cancer cells, Wnt/ β -catenin signaling has been regarded as an important pathway for upregulating EMT-associated gene expression [60,61]. The HH signaling pathway plays an essential role in tumor initiation, metastasis, and maintenance of cancer stem cells [62,63]. In PDGF-induced gliomas, nitric oxide activity drives Notch signaling via the cGMP/PKG pathway, promoting CSC-like characteristics [64]. Several studies have demonstrated that TGF- β functions in cancer progression. EMT induced during normal development and oncogenic transformation is mediated by TGF- β and Notch [65]. TGF- β upregulates the expression of EMT inducers including Snail and Slug, promoting EMT and the acquisition of CSC properties [17,66]. These reports suggest that CSCs utilize these signaling pathways for maintenance.

Significance of the sex determining factor

In our previous study, we have shown that SRY directly increases the expression of OCT4, and promotes self-renewal and chemoresistance of HCCs [67]. In rat HCCs, SRY upregulates SGF29, a component of STAGA histone acetyltransferase complex, and promotes HCC progression via c-Myc signaling pathway [68-71]. The increase in SRY expression in Sertoli cells during testes differentiation is a critical step for sex determination, and it induces sex reversal in female mice [72,73]. The timing of SRY expression determines the fate of the bipotential gonadal ridge [74,75], and SRY interferes with the Wnt signaling pathway required for female sex determination [76-78]. The functional region is limited to the HMG box, which has DNA binding and bending abilities to facilitate transcription [79,80]. A mutation within the HMG box provides a male to female specific phenotype [80]. SRY is involved in the gene network of EMT and serves to stabilize cell plasticity [81]. Several studies have demonstrated an association between SRY and tumor development [68,82,83]. Males have a higher cancer risk than females [84]; therefore, it is possible that SRY contributes to gender disparity in cancer occurrence and progression.



Potential of differentiation therapy

Determining the direction of differentiation would be helpful for certain types of disease, for which a therapeutic strategy has been found. Although it is possible that the differentiation from iPS cells would generate transformed cells, it does not have the potential to transform cells using a direct differentiation strategy. Direct differentiation could be a breakthrough for overcoming neurological disease. Because of four major reprogramming factors, Oct4, Sox2, Klf4, and c-Myc, fibroblasts are transdifferentiated into neural progenitor/stem cells [85]. The minimal set of transcriptional factors, Mash1, Nurr1, and Lmx1a, are sufficient for inducing dopaminergic cells from mouse and human fibroblasts [86]. In addition to these methods, terminally differentiated hepatocytes are converted to functional neuronal cells by the combination of Ascl1, Brn2, and Myt1l [87]. Several studies have shown neural differentiation *in vitro*, and these techniques would provide a novel strategy for Parkinson's or Alzheimer's disease patients.

Some studies have shown that the significance of differentiation of cancer cells into normal tissue cells, which contributes to tumor regression, is induced by some factors, including nutrient conditions, chemicals, and genetic processes. In prostate cancer, androgen deprivation and chemical compounds induced differentiation into neuroendocrine cells [88,89]. Tumor differentiation factors produced by the pituitary gland and secreted into the bloodstream induce the differentiation of prostate and breast cancer [90-92]. In HCC, knockdown of Yap restores hepatocyte differentiation and tumor regression [93], suggesting that restoration of normal function or differentiated phenotypes in cancer cells are related to tumor suppressive function.

Accumulating research has shown the possibility of a differentiation capacity of CSCs. In 1980, differentiation therapy had been adapted to leukemia CSCs (L-CSCs) to induce retinoic acid (RA)-induced differentiation in certain hematopoietic cells [10,11]. It has been well identified that RA, the active form of vitamin A, plays an important role in the induction of neuronal differentiation in mouse embryonal carcinoma lines, P19 and F9 [94-96]. We have recently demonstrated the possibility of differentiation therapy against purified CSCs from HCCs, which differentiated into hepatocytes and neuronal cells induced by BMP4 and RA, respectively [67]. We have confirmed that in the presence of lower concentrations of serum, a high differentiation efficiency is observed, suggesting that lower nutrients affect the status of CSCs. The differentiation capacity of CSCs is well characterized in several types of tumors. For instance, CD133 positive CSCs in HCCs differentiate into hepatocytes induced by BMP4 [97]. The SP fraction of a C6 glioma cell line can produce neuronal and glial cells [98]. Spheroids from ovarian carcinomas show stem cell like properties and have trans-lineage differentiation capacities [99]. Reprogrammed sarcoma cells in the pluripotent state, induced by defined reprogramming factors, induce terminal differentiation into multiple tissue types, although it is a different germ layer [100]. Glioblastoma stem-like cells generate tumor endothelium, suggesting that they control their plasticity for tumor progression [101]. Subpopulations of tumor tissues may eventually acquire stem-like properties via certain nuclear reprogramming factors or some signaling pathways, which in turn, could be therapeutic targets. In summary, two types of therapy have been considered to be effective for tumor tissues (Figure 1). Differentiation therapy could be valuable for CSCs. Matured/differentiated cancer cells may be targets for direct differentiation via the set of lineage-specifying transcriptional factors and conventional chemotherapy.

Our studies show the high potency of differentiation therapy against

the CSC population in HCC. However, at present the differentiation is limited in some tumors and this technique is yet poorly developed. Furthermore, we have no options in the late stages of cancer such as drug refractory and metastasized cancers, which contain considerable CSCs. Therefore, the differentiation strategy requires improvement.

References

- Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, et al. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. *Nature* 367: 645-648.
- Laks DR, Masterman-Smith M, Visnyei K, Angenieux B, Orozco NM, et al. (2009) Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. *Stem Cells* 27: 980-987.
- Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. *Nature* 414: 105-111.
- Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, et al. (2007) Identification of pancreatic cancer stem cells. *Cancer Res* 67: 1030-1037.
- Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, et al. (2006) Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. *Biochem Biophys Res Commun* 351: 820-824.
- Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, et al. (2007) Phenotypic characterization of human colorectal cancer stem cells. *Proc Natl Acad Sci U S A* 104: 10158-10163.
- Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, et al. (2011) Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. *Proc Natl Acad Sci U S A* 108: 7950-7955.
- Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. *Nat Rev Cancer* 9: 265-273.
- Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. *Nat Rev Cancer* 5: 275-284.
- Breitman TR, Selonick SE, Collins SJ (1980) Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. *Proc Natl Acad Sci U S A* 77: 2936-2940.
- Breitman TR, Collins SJ, Keene BR (1981) Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. *Blood* 57: 1000-1004.
- Kawamata H, Tachibana M, Fujimori T, Imai Y (2006) Differentiation-inducing therapy for solid tumors. *Curr Pharm Des* 12: 379-385.
- Magee JA, Piskounova E, Morrison SJ (2012) Cancer stem cells: Impact, heterogeneity, and uncertainty. *Cancer Cell* 21: 283-296.
- Li F, Tiede B, Massagué J, Kang Y (2007) Beyond tumorigenesis: Cancer stem cells in metastasis. *Cell Res* 17: 3-14.
- Stingl J, Caldas C (2007) Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. *Nat Rev Cancer* 7: 791-799.
- Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. *Proc Natl Acad Sci U S A* 100: 3983-3988.
- Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* 133: 704-715.
- Liu S, Cong Y, Wang D, Sun Y, Deng L, et al. (2013) Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. *Stem Cell Reports* 2: 78-91.
- Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, et al. (2010) CD13 is a therapeutic target in human liver cancer stem cells. *J Clin Invest* 120: 3326-3339.
- Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, et al. (2008) Significance of CD90+ cancer stem cells in human liver cancer. *Cancer Cell* 13: 153-166.
- Yang ZF, Ngai P, Ho DW, Yu WC, Ng MN, et al. (2008) Identification of local and circulating cancer stem cells in human liver cancer. *Hepatology* 47: 919-928.
- He G, Dhar D, Nakagawa H, Font-Burgada J, Ogata H, et al. (2013) Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. *Cell* 155: 384-396.

23. Sun YF, Xu Y, Yang XR, Guo W, Zhang X, et al. (2013) Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. *Hepatology* 57: 1458-1468.
24. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, et al. (2007) Isolation of rare circulating tumour cells in cancer patients by microchip technology. *Nature* 450: 1235-1239.
25. Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, et al. (2014) Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. *Cell* 158: 1110-1122.
26. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, et al. (2013) Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. *Science* 339: 580-584.
27. Mirzaei A, Tavoosidana G, Modarressi MH, Rad AA, Fazeli MS, et al. (2015) Upregulation of circulating cancer stem cell marker, DCLK1 but not Lgr5, in chemoradiotherapy-treated colorectal cancer patients. *Tumour Biol* 36: 4801-4810.
28. Scharenberg CW, Harkey MA, Torok-Storb B (2002) The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. *Blood* 99: 507-512.
29. Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, et al. (2002) The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. *Clin Cancer Res* 8: 22-28.
30. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, et al. (2005) Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. *Cancer Res* 65: 6207-6219.
31. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, et al. (2004) A distinct "side population" of cells with high drug efflux capacity in human tumor cells. *Proc Natl Acad Sci U S A* 101: 14228-14233.
32. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, et al. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. *Cell* 77: 491-502.
33. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, et al. (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. *Proc Natl Acad Sci U S A* 95: 15665-15670.
34. Dean M (2009) ABC transporters, drug resistance, and cancer stem cells. *J Mammary Gland Biol Neoplasia* 14: 3-9.
35. Chartrain M, Riond J, Stenvenin A, Vandenberghie I, Gomes B, et al. (2012) Melanoma chemotherapy leads to the selection of ABCB5-expressing cells. *PLoS One* 7: e36762.
36. Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dolinska-Krajewska B, et al. (2006) ABC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. *Clin Cancer Res* 12: 7149-7158.
37. Vasilyeva A, Durmus S, Li L, Wagenaar E, Hu S, et al. (2015) Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b. *Cancer Res* 75: 2729-2736.
38. Lagas JS, Vlamming ML, van Tellingen O, Wagenaar E, Jansen RS, et al. (2006) Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. *Clin Cancer Res* 12: 6125-6132.
39. Campa D1, Müller P, Edler L, Knoefel L, Barale R, et al. (2012) A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis. *Int J Cancer* 131: 2920-2928.
40. Simon N, Marsot A, Villard E, Choquet S, Khe HX, et al. (2013) Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy. *Pharmacogenomics J* 13: 507-513.
41. Noh KH, Kim BW, Song KH, Cho H, Lee YH, et al. (2012) Nanog signaling in cancer promotes stem-like phenotype and immune evasion. *J Clin Invest* 122: 4077-4093.
42. Bae KM, Su Z, Frye C, McClellan S, Allan RW, et al. (2010) Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. *J Urol* 183: 2045-2053.
43. Leis O, Eguirra A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, et al. (2012) Sox2 expression in breast tumours and activation in breast cancer stem cells. *Oncogene* 31: 1354-1365.
44. Jeter CR, Badeaux M, Choy G, Chandra D, Patrawala L, et al. (2009) Functional evidence that the self-renewal gene NANOG regulates human tumor development. *Stem Cells* 27: 993-1005.
45. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126: 663-676.
46. Chambers I, Tomlinson SR (2009) The transcriptional foundation of pluripotency. *Development* 136: 2311-2322.
47. Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, et al. (2010) Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. *Cancer Res* 70: 10433-10444.
48. Luo W, Li S, Peng B, Ye Y, Deng X, et al. (2013) Embryonic stem cells markers SOX2, OCT4 and Nanog expression and their correlations with epithelial-mesenchymal transition in nasopharyngeal carcinoma. *PLoS One* 8: e56324.
49. Linn DE, Yang X, Sun F, Xie Y, Chen H, et al. (2010) A Role for OCT4 in Tumor Initiation of Drug-Resistant Prostate Cancer Cells. *Genes Cancer* 1: 908-916.
50. Jia Q, Zhang X, Deng T, Gao J (2013) Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)/CD133(+) liver cancer stem cells. *Cell Reprogram* 15: 143-150.
51. Wang XQ, Ongkeko WM, Chen L, Yang ZF, Lu P, et al. (2010) Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. *Hepatology* 52: 528-539.
52. Herreros-Villanueva M, Zhang JS, Koenig A, Abel EV, Smyrk TC, et al. (2013) SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. *Oncogenesis* 2: e61.
53. Lee SH, Oh SY, Do SI, Lee HJ, Kang HJ, et al. (2014) SOX2 regulates self-renewal and tumorigenicity of stem-like cells of head and neck squamous cell carcinoma. *Br J Cancer* 111: 2122-2130.
54. Bourguignon LY, Peyrollier K, Xia W, Gilad E (2008) Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. *J Biol Chem* 283: 17635-17651.
55. Kashyap V, Rezende NC, Scotland KB, Shaffer SM, Persson JL, et al. (2009) Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. *Stem Cells Dev* 18: 1093-1108.
56. Takebe N, Miele L, Harris PJ, Jeong W, Bando H, et al. (2015) Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. *Nat Rev Clin Oncol* 12: 445-464.
57. Shin K, Lee J, Guo N, Kim J, Lim A, et al. (2011) Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. *Nature* 472: 110-114.
58. Katoh M (2011) Network of WNT and other regulatory signaling cascades in pluripotent stem cells and cancer stem cells. *Curr Pharm Biotechnol* 12: 160-170.
59. Wong VW, Stange DE, Page ME, Buczacck S, Wabik A, et al. (2012) Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling. *Nat Cell Biol* 14: 401-408.
60. Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, et al. (2007) Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. *Cancer Cell* 12: 559-571.
61. Lu Z, Ghosh S, Wang Z, Hunter T (2003) Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. *Cancer Cell* 4: 499-515.
62. Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, et al. (2004) Hedgehog signalling in prostate regeneration, neoplasia and metastasis. *Nature* 431: 707-712.
63. Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, et al. (2009) Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. *Nature* 458: 776-779.
64. Charles N, Ozawa T, Squatrito M, Bleau AM, Brennan CW, et al. (2010) Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. *Cell Stem Cell* 6: 141-152.

65. Timmerman LA, Grego-Bessa J, Raya A, Bertran E, Perez-Pomares JM, et al. (2004) Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. *Genes Dev* 18: 99-115.
66. Medici D, Hay ED, Olsen BR (2008) Snail and Slug promote epithelial-mesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factor-beta3. *Mol Biol Cell* 19: 4875-4887.
67. Murakami S, Ninomiya W, Sakamoto E, Shibata T, Akiyama H, et al. (2015) SRY and OCT4 Are Required for the Acquisition of Cancer Stem Cell-Like Properties and Are Potential Differentiation Therapy Targets. *Stem Cells* 33: 2652-2663.
68. Murakami S, Chishima S, Uemoto H, Sakamoto E, Sato T, et al. (2014) The male-specific factor Sry harbors an oncogenic function. *Oncogene* 33: 2978-2986.
69. Kurabe N, Murakami S, Tashiro F (2015) SGF29 and Sry pathway in hepatocarcinogenesis. *World J Biol Chem* 6: 139-147.
70. Kurabe N, Katagiri K, Komiya Y, Ito R, Sugiyama A, et al. (2007) Dereglated expression of a novel component of TFC/STAGA histone acetyltransferase complexes, rat SGF29, in hepatocellular carcinoma: Possible implication for the oncogenic potential of c-Myc. *Oncogene* 26: 5626-5634.
71. Bian C, Xu C, Ruan J, Lee KK, Burke TL, et al. (2011) Sgf29 binds histone H3K4me2/3 and is required for SAGA complex recruitment and histone H3 acetylation. *EMBO J* 30: 2829-2842.
72. Koopman P, Gubbay J, Vivian N, Goodfellow P, Lovell-Badge R (1991) Male development of chromosomally female mice transgenic for Sry. *Nature* 351: 117-121.
73. Sinclair AH, Berta P, Palmer MS, Hawkins JR, Griffiths BL, et al. (1990) A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif. *Nature* 346: 240-244.
74. Hiramatsu R, Matoba S, Kanai-Azuma M, Tsunekawa N, Katoh-Fukui Y, et al. (2009) A critical time window of Sry action in gonadal sex determination in mice. *Development* 136: 129-138.
75. Bullejos M, Koopman P (2001) Spatially dynamic expression of Sry in mouse genital ridges. *Dev Dyn* 221: 201-205.
76. Tamashiro DA, Alarcón VB, Marikawa Y (2008) Ectopic expression of mouse Sry interferes with Wnt/beta-catenin signaling in mouse embryonal carcinoma cell lines. *Biochim Biophys Acta* 1780: 1395-1402.
77. Bernard P, Sim H, Knowler K, Vilain E, Harley V (2008) Human SRY inhibits beta-catenin-mediated transcription. *Int J Biochem Cell Biol* 40: 2889-2900.
78. Tomizuka K, Horikoshi K, Kitada R, Sugawara Y, Iba Y, et al. (2008) R-spondin1 plays an essential role in ovarian development through positively regulating Wnt-4 signaling. *Hum Mol Genet* 17: 1278-1291.
79. Mitchell CL, Harley VR (2002) Biochemical defects in eight SRY missense mutations causing XY gonadal dysgenesis. *Mol Genet Metab* 77: 217-225.
80. Phillips NB, Jancso-Radek A, Ittah V, Singh R, Chan G, et al. (2006) SRY and human sex determination: The basic tail of the HMG box functions as a kinetic clamp to augment DNA bending. *J Mol Biol* 358: 172-192.
81. Venkov C, Plieth D, Ni T, Karmaker A, Bian A, et al. (2011) Transcriptional networks in epithelial-mesenchymal transition. *PLoS One* 6: e25354.
82. Xue TC, Zhang L, Ren ZG, Chen RX, Cui JF, et al. (2015) Sex-determination gene SRY potentially associates with poor prognosis but not sex bias in hepatocellular carcinoma. *Dig Dis Sci* 60: 427-435.
83. Hersmus R, van der Zwan YG, Stoop H, Bernard P, Sreenivasan R, et al. (2012) A 46,XY female DSD patient with bilateral gonadoblastoma, a novel SRY missense mutation combined with a WT1 KTS splice-site mutation. *PLoS One* 7: e40858.
84. Dorak MT, Karpuzoglu E (2012) Gender differences in cancer susceptibility: An inadequately addressed issue. *Front Genet* 3: 268.
85. Kim J, Efe JA, Zhu S, Talantova M, Yuan X, et al. (2011) Direct reprogramming of mouse fibroblasts to neural progenitors. *Proc Natl Acad Sci U S A* 108: 7838-7843.
86. Caiazzo M, Dell'Anno MT, Dvoretzskova E, Lazarevic D, Taverna S, et al. (2011) Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. *Nature* 476: 224-227.
87. Marro S, Pang ZP, Yang N, Tsai MC, Qu K, et al. (2011) Direct lineage conversion of terminally differentiated hepatocytes to functional neurons. *Cell Stem Cell* 9: 374-382.
88. Yuan TC, Veeramani S, Lin FF, Kondrikou D, Zelivianski S, et al. (2006) Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. *Endocr Relat Cancer* 13: 151-167.
89. Valentini A, Biancoletta M, Amati F, Gravina P, Miano R, et al. (2007) Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line. *Drug Metab Dispos* 35: 968-972.
90. Platica M, Ivan E, Holland JF, Ionescu A, Chen S, et al. (2004) A pituitary gene encodes a protein that produces differentiation of breast and prostate cancer cells. *Proc Natl Acad Sci U S A* 101: 1560-1565.
91. Sokolowska I, Woods AG, Gawinowicz MA, Roy U, Darie CC (2012) Identification of a potential tumor differentiation factor receptor candidate in prostate cancer cells. *FEBS J* 279: 2579-2594.
92. Sokolowska I, Woods AG, Gawinowicz MA, Roy U, Darie CC (2012) Identification of potential tumor differentiation factor (TDF) receptor from steroid-responsive and steroid-resistant breast cancer cells. *J Biol Chem* 287: 1719-1733.
93. Fitamant J, Kottakis F, Benhamouche S, Tian HS, Chuvin N, et al. (2015) YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. *Cell Rep*.
94. Jones-Villeneuve EM, McBurney MW, Rogers KA, Kainins VI (1982) Retinoic acid induces embryonal carcinoma cells to differentiate into neurons and glial cells. *J Cell Biol* 94: 253-262.
95. Jones-Villeneuve EM, Rudnicki MA, Harris JF, McBurney MW (1983) Retinoic acid-induced neural differentiation of embryonal carcinoma cells. *Mol Cell Biol* 3: 2271-2279.
96. Liesi P, Rechardt L, Wartiovaara J (1983) Nerve growth factor induces adrenergic neuronal differentiation in F9 teratocarcinoma cells. *Nature* 306: 265-267.
97. Zhang L, Sun H, Zhao F, Lu P, Ge C, et al. (2012) BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma. *Cancer Res* 72: 4276-4285.
98. Kondo T, Setoguchi T, Taga T (2004) Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. *Proc Natl Acad Sci U S A* 101: 781-786.
99. Liu KC, Yo YT, Huang RL, Wang YC, Liao YP, et al. (2013) Ovarian cancer stem-like cells show induced translineage-differentiation capacity and are suppressed by alkaline phosphatase inhibitor. *Oncotarget* 4: 2366-2382.
100. Zhang X, Cruz FD, Terry M, Remotti F, Matushansky I (2013) Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. *Oncogene* 32: 2249-2260, 2260.
101. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, et al. (2010) Glioblastoma stem-like cells give rise to tumour endothelium. *Nature* 468: 829-833.